ClinicaliQ Trial Snapshot
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Active Not Recruiting • Phase II • Cardiology / Cardiovascular • NCT03492177.
- Study testing whether adult-based selexipag doses produce similar blood levels in children aged 2-18 with pulmonary arterial hypertension.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=) 2 to less than (˂) 18 years of age with Pulmonary Arterial Hypertension (PAH), by investigating the PK of selexipag and its active metabolite ACT-333679 in this population. Conditions: Pulmonary Arterial Hypertension Interventions: selexipag (Uptravi) Lead Sponsor: Actelion Planned Enrollment: 63 participants